Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in metastatic adult granulosa cell tumor of the ovary
NCT06254781Completed
- Sponsor
- University Health Network
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label trial of luspatercept in Adult granulosa cell tumor of the ovary (AGCT), sponsored by University Health Network. Primary endpoints: Objective response at 3 months, Eastern Cooperative Oncology Group performance status at 3 months and 1 more. Started May 2022; status: completed.
02
Drugs
luspatercept
03
Conditions
Adult granulosa cell tumor of the ovary (AGCT)
Beyond the preview
Go deeper on NCT06254781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254781.